An NCI-designated Comprehensive Cancer Center
By City of Hope | August 20, 2019

An estimated 20,000 to 30,000 human papillomavirus-associated cancers are diagnosed annually in the United States. HPV16-induced cancers, a strain that causes about 70% of all cervical cancers worldwide, are ideal candidates for targeted T cell therapy due to their nonself antigens.

Those antigens can be readily recognized by immune cells inducing T cell activation. While T cell therapy has been well-recognized in hematological cancers, limited research has been done in solid tumor treatment as it presents a major hurdle due to these tumors’ immunosuppressive nature.

Our investigators are leading the way in this arena. They launched the first-in-human, phase 1 trial that utilizes genetically engineered human T cells with KITE-439 receptors for the treatment of patients with relapsed or resistant HPV-associated cancers. This engineered receptor works on targeting antigens expressed in cancer cells that are infected by HPV, leading to a T cell activation against the cells. Adult, HLA-A201 positive patients with relapsed/refractory HPV16 solid tumors are now being enrolled in this two-part, open-label study sponsored by Kite Pharma.

The principal investigator is Erminia Massarelli, M.D., Ph.D., M.S., an associate clinical professor in the Department of Medical Oncology & Therapeutics Research, specializing in lung and head and neck cancers. The study focuses on the safety and efficacy of KITE-439. Patients will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by a single dose of KITE-439.

While enrolling adults who had at least one line of therapy, including systematic chemotherapy, the first part of the study will evaluate the dose-limiting toxicity after a single dose of KITE-439. Based on the selected dose, part two will evaluate the efficacy of the intervention by measuring the objective response rate.

Have a patient who may be a candidate for T cell therapy?

Call the dedicated T cell therapy referral line, 833-310-CART (2278), or visit CityofHope.org.

For a full listing of clinical trials, visit clinicaltrials.coh.org.

****

Subscribe to Physician News for the latest developments in diabetes and cancer prevention, treatment, research, clinical trials and upcoming continuing medical education (CME) programs.
 
We will always respect your privacy and you may unsubscribe at any time. We will never sell or exchange your information with others. View our complete Privacy Policy .

*Required Fields